

Stakeholder perspectives on conducting PK studies in pregnant individuals

Public health and academic perspective

FDA-University of Maryland CERSI Pharmacokinetic Evaluation
in Pregnancy Public Workshop- May 16, 2022


Martina Penazzato MD, MSc, PhD
World Health Organization
Geneva-Switzerland



Addressing the specific needs of a large proportion of people in need of ARVs

- In 2020, there were an estimated 19.9 million women living with HIV and 600,000 women over 15 years old newly acquired HIV infection in 2020¹
- 225 million women have an unmet need for family planning annually.²
- **There were an estimated 1.3 million births to women living with HIV in 2020³**
- With expansion of ‘treat all’ and rollout of PrEP, **increasing numbers of women are conceiving while already on antiretrovirals (ARVs).**¹
- **Physiologic changes of pregnancy can affect drug absorption, distribution, biotransformation, and elimination.**
- **ARVs in pregnancy can be associated with adverse birth outcomes and/or toxicities particular to pregnant women and their babies.**
- **Delayed introduction of new ARVs** for pregnant and breastfeeding women limits regimen harmonization across populations and, in turn, impedes ART and PrEP scale up efforts

Time from FDA drug approval to first published pharmacokinetics data in pregnancy, HIV drugs



80% of women take a drug in pregnancy with minimal safety/efficacy data

Pregnant women are excluded from registrational drug trials resulting in delayed study of ARVs in pregnancy



Historical approach aims primarily to **protect the fetus/infant** from harm



Many disincentives for industry, funders & researchers to include pregnant / lactating women in trials



Full nonclinical developmental and reproductive toxicology (DART) data often not available until **late** in drug development



Most current pregnancy/lactation data arise from **postmarketing opportunistic studies** of women receiving antiretrovirals for clinical care



Minimal systematic **post-marketing surveillance** or observational studies that evaluate pregnancy and other outcomes following drug licensure and widespread use

A paradigm shift is underway

- Over the past five years, multiple stakeholders have voiced their concerns around the exclusion of pregnant women from pre- and post-licensure drug trials and the associated harms and risks of these policies.
- The Pregnancy + HIV/AIDS Seeking Equitable Study (PHASES), “Ending the Evidence Gap for Pregnant Women around HIV & Co-infections”, identified three major conceptual shifts that will facilitate the inclusion of pregnant women in research:
 1. considering pregnant women as a complex population rather than a vulnerable population
 2. moving from protecting from research to protecting through research
 3. promoting fair inclusion in, rather than presumptive exclusion from, clinical drug trials
- Paradigm shift requires a multi-stakeholder approach




WHO & IMPAACT Dec 2019: advancing pharmacology studies in pregnant and breastfeeding women with HIV



APPROACHES TO OPTIMIZE AND ACCELERATE PHARMACOLOGY STUDIES IN PREGNANT AND LACTATING WOMEN

MEETING REPORT 13–14 JUNE 2019
WASHINGTON, DC, USA

Proposed approach to pharmacokinetic studies of ARVs during pregnancy and the postpartum period



WHO & IMPAACT Dec 2020: “Approaches to Enhance and Accelerate Study of New Drugs for HIV and Associated Infections in Pregnant Women”




Organizing committee

Martina Penazzato (WHO)
Elaine Abrams (ICAP at Columbia U/IMPAACT)
Alexandra Calmy (U of Geneva)
Shahin Lockman (Harvard U)
Angela Colbers (Radboud U)
Marissa Vicari (CIPHER)
Francois Renaud (WHO)
Polly Clayton (HIV i-BASE)
Imelda Mahaka (Pangaea Zimbabwe AIDS Trust)
Jennifer Zech (ICAP at Columbia U)

Academic researchers, regulators, clinical experts, industry leaders, funders, civil society, ethicists, other key stakeholders

Workshop part 1 December 8th and 10th, 2020



Workshop part 2 July 6th-7th, 2021

Women should be supported to **CHOOSE** whether to take part in a trial

- Women want and need a good evidence base for treatment in pregnancy
- Unfair/coercive to require contraception in order to take part in a trial
- Women can benefit directly from taking part in trials
- Essential to provide information in a clear and transparent manner
- Women should be involved in every stage of clinical trial planning and conduct



Key principles for studying new antiretrovirals in pregnancy

If the agent is **efficacious in non-pregnant adults** (viral load suppression) and **adequate drug exposures** are achieved in pregnancy, then **efficacy can be assumed** in pregnancy without additional trials.

If the agent is efficacious in non-pregnant adults (viral load suppression) and adequate drug exposures are achieved in pregnancy, **efficacy for prevention of vertical transmission can be inferred**.

All new agents must to be studied in pregnant people for **pharmacokinetics/optimal dosing and short-term safety**.

Dedicated pregnancy safety studies assessing pregnancy, birth and infant outcomes should be conducted for all **new ARVs with expected broad use** in pregnant women and women who may become pregnant.

There is **no expectation to have meaningful clinical information about teratogenicity risk before registration**; Large numbers of observations with exposure at conception/early pregnancy are needed to identify increased risk of rare events and will only come through post marketing surveillance/registries/Phase 4 studies.

Once **pharmacokinetic/dosing and short-term safety** in pregnancy are determined to be adequate, there should be no restrictions to access to during pregnancy once the ARV is licensed.

Current approach to inclusion of pregnant women in pre-licensure studies of new antiretroviral agents



A new framework to expedite the timelines for the study of new ARVs in pregnancy

Involve women of childbearing potential living with HIV from the identification of research questions through the study design, recruitment, conduct, and dissemination of results.

Perform non-clinical developmental and reproductive toxicology studies (DART) earlier during drug development for all new HIV agents:

- Fertility and early embryonic development (FEED) and embryo-fetal development (EFD) studies should be completed during or no later than the end of the phase 2 registrational trials.
- Pre- and postnatal development (PPND) studies should be completed during early phase 3 or no later than the end of phase 3 registrational trial


Women who become pregnant in registrational trials should be given the **option to make an informed choice to stay on study drug once early non-clinical FEED and EFD studies are completed**, with no negative signals and dosing is established in non-pregnant people.

Enroll pregnant women in specific studies to determine **PK and preliminary safety as soon as late non-clinical PPND studies are completed** with no negative signals for all new HIV agents.


Investigate adverse **maternal, pregnancy and birth outcomes through dedicated pregnancy safety studies for all new priority HIV agents** identified through CADO as soon as dosing is confirmed.

Expand systematic and rigorous active safety surveillance studies to enable systematic and rapid detection of adverse birth outcomes and rare events such as birth defects associated with exposure to antiretrovirals during pregnancy.


Current approach to inclusion of pregnant women in pre-licensure studies of new antiretroviral agents



New Collaborative Conceptual Framework for Surveillance of Safety of ARVs in Pregnancy



Current approach to inclusion of pregnant women in pre-licensure studies of new antiretroviral agents



Are there success stories to learn from?

Current approach to inclusion of pregnant women in pre-licensure studies of new antiretroviral agents



- **Rolling protocols established to assess PK** and confirm dosing in pregnant and lactating women in post-marketing phase
- **Active surveillance** established that can prospectively follow multiple regimens and formulations and compare one to another in the postmarketing phase
- **Removal of contraceptive requirement** and possibility of remaining on study drug (post-approval)
- Well conducted **dedicated safety study** assessing maternal, birth and infant outcomes
- **Removal of contraceptive requirement** and collection of PK data should participants become pregnant and choose to stay on the study drug (pre-approval).

LENACAPAVIR ★

IMPACT 2026s/PANNA ★

Tsepamo ★

HPTN 084 extension ★

★ VESTED IMPAACT 2010

TO MOVE FORM THEORY TO PRACTICE we need urgent actions...BUT No one can do this alone...therefore We need a concerted effort to ensure that women are not left behind



- Civil society and community-based organizations



- Regulators



- Researchers



- Industry



- Funders



- Institutional Review Boards and Ethics Committees



- Publishers



- WHO

**Launched on
Dec 1st, 2021**




CIPHER
Paediatric HIV
Matters
RIAS

Research for informed choices: Accelerating the study of new drugs for HIV in pregnant and breastfeeding women

A call to action






Regulators



- Develop **guidance** on the **acceptable minimal data** to include in the **product information** notice in order to enable pregnancy-specific studies.
- Revise expected **timing** of non-clinical **developmental and reproductive toxicity** studies so that they are **completed earlier** (as defined in the framework).
- **Encourage and support** allowing women who **become pregnant** in clinical trials to choose to **stay on the study drug** and contribute pregnancy PK and safety data (after dosing is established in PK studies in non-pregnant women and if no major concern is raised by non-clinical FEED/EFD studies).
- Identify ways to **encourage enrolment** of **pregnant women in Phase 3** pre-licensure of non-pregnant adults and in post-approval Phase 4 trials for priority agents for HIV treatment and prevention.



Regulators



- **Strongly recommend** that **PK in pregnancy** be available at the time of licensure of all new agents for HIV prevention and treatment.
- **Promote** the conduct of dedicated **pregnancy safety trials** for **priority** HIV agents (either during Phase 3 trials in non-pregnant women or early post-registration).
- **Promote and support** use of standardized and harmonized methods for **active surveillance of safety** of HIV agents in pregnancy.
- **Encourage** systematic reporting of **pregnancy safety data** from a network of sites or collected in active surveillance programmes to a **global pregnancy registry**.
- **Foster alignment between regulatory agencies** on the above-described key principles and their implementation.

Next Steps

- Utilize existing **political platforms** to galvanize commitment and promote accountability.
- **Journal Supplement** in JIAS for wide dissemination to the scientific community.
- Continue the technical dialogue and implementation of strategic actions through **WHO-convened working group**.
- Leverage multiple fora to disseminate the key principles and **engage with the constituencies** that can contribute and take action.



Organizing committee



Elaine Abrams
(Columbia University)



Alexandra Calmy
(University of Geneva)



Polly Clayden
(HIV i-Base)



Angela Colbers
(Radboud University)



Shahin Lockman
(Harvard University)



Imelda Mahaka
(PANGEA)



Martina Penazzato
(WHO)



Francoise Renaud
(WHO)



Marissa Vicari
(IAS/CIPHER)



Jennifer Zech
(ICAP at Columbia University)

Thank you

For more information, please contact:

WHO: Martina Penazzato penazzatom@who.int

and Francoise Renaud renaudf@who.int

IMPAACT: Elaine Abrams eja1@cumc.columbia.edu

